One more vaccine enters testing phase

Pfizer said Tuesday it has begun testing an experimental vaccine to combat the coronavirus in the United States.

The U.S.-based pharmaceutical giant, which is working alongside German drugmaker BioNTech, said the first human participants in the United States have been dosed with the potential vaccine, BNT162. They began human trials of the experimental vaccine late last month in Germany.

“With our unique and robust clinical study program underway, starting in Europe and now the U.S., we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most,” Pfizer Chairman and CEO Albert Bourla said in a statement.

“The short, less than four-month time frame in which we’ve been able to move from preclinical studies to human testing, is extraordinary,” he added.

The experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response for the virus.

The trial will test the experimental vaccine on adults ages 18 to 55 in the first stage before moving on to older groups, the company said, adding it hopes to test up to 360 people. (CNBC)

 



Share on Google Plus

About Unknown

Sri Lanka's most important news collector. We publish news from the trusted websites in the world.

0 comments:

Post a Comment